Basilea Pharmaceutica has shared that the FDA has approved ZEVTERA as a treatment for adult patients suffering from Staphylococcus aureus bloodstream infections, inclusive of those with right-sided infective endocarditis. This approval also extends to adults with acute bacterial skin ailments and skin structure infections, as well as both adult and pediatric patients with community-acquired bacterial pneumonia.
Basliea's Chief Medical Officer, Marc Engelhardt, expressed his satisfaction with the FDA's approval of ZEVTERA for all three submitted indications in the New Drug Application, emphasizing its inclusion in pediatric labeling.
For more health-related news, visit rttnews.com.
